Get started

Multibagger

AVTNPL Showing Good MomentumNSE:AVTNPL ............................................................................................................................................................................................................................................ Products The main products of the Co. are - Marigold Extracts for Eye Care, Food Coloring & Poultry Pigmentation; Spice oleoresin and Oils for Food Coloring and Flavoring; Value added Teas - Decaffeinated Teas and Instant Teas; Animal Nutrition Products; and Rosemary extract. ............................................................................................................................................................................................................................................ Subsidiaries The Co. has 2 wholly owned subsidiaries, namely AVT Natural Europe Ltd. & AVT Natural S.A. De C.v., Mexico. AVT Natural Europe Ltd. is the marketing arm of the Company for decaffeinated tea and instant tea. AVT Natural SA DE C.V, Mexico has been established with an aim to capture the market for the Animal Nutritional products in the South American market and other markets. ............................................................................................................................................................................................................................................
NSE:AVTNPLLong
by iism-ExpertTrading
IOLCP Showing Change in Structure can go towards 52 Week HighNSE:IOLCP ...................................................................................................................... ...................................................................................................................... The Company’s turnover increased to ₹ 2,133 crore in FY24 from ₹ 983 crore in FY18 at a CAGR of 13.77% ...................................................................................................................... ...................................................................................................................... The share of regulated market sale has increased to ₹ 300 crore in FY24 from ₹100 crore in FY18 ...................................................................................................................... ...................................................................................................................... Increased contribution of non-Ibuprofen drugs from ₹35 crore in FY18 to ₹431 crore in FY24, showing a steady upward trend over the years ...................................................................................................................... ...................................................................................................................... Added more than 10 products since 2017 in APIs and chemical segments. The Company has recently commenced a new plant of Acetic Anhydride ...................................................................................................................... ...................................................................................................................... • The Indian API market is expected to grow at a CAGR of 13.7% over the four years. • India hosts 500 API manufacturers, contributing approximately 8% to the global API Industry. • As the largest supplier of generic medicines, India manufactures around 60,000 different generic brands across 60 therapeutic categories. • In FY24 India saw a 4.12% increase in the total imports of bulk drugs and intermediates, amounting to ₹ 37,721.88 crore, compared to ₹ 36,229.15 crore in FY23. • Indian medicines are preferred worldwide due to their combination of low price and high quality, earning India the title of "pharmacy of the world." ...................................................................................................................... ...................................................................................................................... Positive factors • Strongly improving operating performance, resulting in growth of more than 15% in total operating income and sustained EBIDTA margin of more than 20%, on a sustained. • Diversifying product portfolio and reducing dependency on its main product Ibuprofen and ethyl acetate to below 65% in the overall revenue. • Improving total debt to gross cash accruals (TD/GCA) and TD to profit before interest, lease rentals, depreciation, and taxation (TD/PBILDT) to below unity. ...................................................................................................................... ...................................................................................................................... Established market position and diversified product offering The company was incorporated, 1986 with the commencement of business in chemical segment. In 2000, the company started production of Ibuprofen. IOLCPL is one of the largest manufacturers of Ibuprofen with significant global share and the company is backward integrated for manufacturing Ibuprofen. IOLCPL has a market presence across more than 50 countries with sales contribution from exports forming around 28% of total sales in FY24 (PY: 29%). The company’s overseas customers are spread across Switzerland, Bangladesh, Spain, Indonesia, Hungary, United Kingdom, Nepal, China, Turkey and Japan, among others. The company is one of the largest manufacturers of Ibuprofen (capacity of 12000 MTPA) and has the second largest manufacturing capacity (12000MTPA) for Iso Butyl Benzene (key raw material for Ibuprofen)
NSE:IOLCPLong
by iism-ExpertTrading
RUPA indicating is No More an Ordinary Underwear BrandNSE:RUPA Commenting on the financial performance Mr. Vikash Agarwal - Whole Time Director, said, “We are pleased to report a stable performance in Q1 FY25, though the industry continues to witness resistance to any price increase. We demonstrated steady improvements across key financial metrics. This quarter, we witnessed 8% rise in revenue, primarily driven by strong sales in our core product line. Our volume growth for the quarter reached 9%, supported by strong sales in the economy and athleisure segments. Our EBITDA saw a year-on-year increase of 59%, totaling Rs. 18.0 crores for the quarter, showcasing our commitment to cost management and operational efficiency. Operating margins also improved by 280 basis points compared to the same period last year. Furthermore, our net profit experienced substantial growth of 149%, reaching Rs. 10.5 crores for the quarter. This underscores the effectiveness of our financial strategies and the resilience of our business model. Net profit margins improved by 280 basis points during the quarter. Notably, our exports have shown progress, with a healthy 32% year-on-year growth, reaching Rs. 8 crores. This reflects our steady penetration into international markets. Revenue contribution from Modern Trade remains robust at 8% in Q1 FY25. The pilot project “Pragati’, which was launched last quarter, has received encouraging feedback from our distributors. We expect healthy expansion of the project going forward. Our cash flow from operations remains strong, generating Rs. 44 crores in Q1 FY25. We have made significant progress in reducing our debt, achieving a net debt-free status as at end of Q1 FY25. Our branding and advertising strategies accounted for 9% of revenues in Q1 FY25. Looking ahead, we are confident in achieving new business milestones and delivering innovative products to our diverse customer segments. Our customer-first approach will help us strengthen our position as an industry leader and contribute to our sustainable business model
NSE:RUPALong
by iism-ExpertTrading
KOPRAN Showed Breakout with Huge Volume at 52 Weeks High ZoneNSE:KOPRAN The co. has set up a new API plant at Panoli, commercial production at this facility is expected to be started from Q3 FY25. In FY23, it completed upgradation and expansion of the multi-product plant at the Mahad facility for existing products and to manufacture new molecules. An integrated Pharmaceutical Company, committed to supplying International Quality Formulations and Active Pharmaceutical Ingredients (APIs) globally. State-of-the-art manufacturing facilities and products with various accreditations and approvals by major global regulatory authorities. The formulations vertical is operated through Kopran Limited. The API vertical is being operated under Kopran Research Laboratories Ltd. (KRLL), a wholly owned subsidiary of Kopran Limited
NSE:KOPRANLong
by iism-ExpertTrading
FIEMIND Turned ON its Marubozu Headlights At ALL TIME HIGH ZONE NSE:FIEMIND GOVT. APPROVED R&D CENTRE • FIEM’s state of the art R&D Centre offers its clients design and development capabilities in Automotive Lighting & Signalling Equipments and Rear View Mirrors which meet the specifications of the clients requirements. • Government of India, Ministry of Science and Technology, Department of Science and Industrial Research has accorded Recognition to Company’s in-house R&D Unit situated at Rai Industrial Estate, Sonepat. • The Company’s R&D Centre is established with modern infrastructure, state-of-the-art technology, equipped with latest software, qualified and experienced manpower. • FIEM’s in-house R&D Centre has various kinds of testing facilities such as Product Testing, Photometry Testing, Environmental Testing, Thermal Tests, Electronic Test, Vibration Test, Chemical Test, Mechanical Tests etc. • Photometry Laboratory of the Company is NABL Accredited. • Some examples of R&D conducted by company: • In-house design and development of Railway IPIS (Integrated Passenger Information Systems with LED Display) • In-house design and development for four wheeler LED Rear combination, LED direction indicator light etc. • Advantages of in-house R&D unit: • Diversified and large portfolio of lighting products developed. • New generation LED technology in automotive and home lighting segments developed. • Reduction in development time and cost savings to clients. Company is almost debt free. Company has delivered good profit growth of 24.4% CAGR over last 5 years Company has been maintaining a healthy dividend payout of 29.3%
NSE:FIEMINDLong
by iism-ExpertTrading
INDOAMIN Showing Volume Strength near ALL TIME HIGH Zone NSE:INDOAMIN Strengths: Established market position: IAL was promoted by Mr Vijay B Palkar in 1979, as Techno Chemical Industries, and converted to IAL in 1992. Over the years, the promoters have developed strong expertise in the chemical industry. The company now manufactures oleo, specialty and performance chemicals, used across various industries, such as pharmaceuticals, agrochemicals, fertilizers, petrochemicals, pesticides and perfumeries. Benefits from the longstanding presence of the promoters in the chemical industry and their established relationships with customers and suppliers will continue over medium term. Above average financial risk profile: The financial risk profile is above average with a robust net worth of around Rs. 213.86 crore as on March 31, 2023. This supports the financial flexibility of the group. Supported by a robust net worth the capital structure is moderate with total outside liabilities to adjusted networth (TOLANW) of 1.72 time as on March 31, 2023. This is expected to remain comfortable going forward. Capital structure is expected to improve over medium term on the back of healthy accruals, absence of large debt funded capex and scheduled repayments. Overall financial risk profile is expected to further improve over medium term.
NSE:INDOAMINLong
by iism-ExpertTrading
EPL Ltd. - A 360° Analysis: TechnoFunda & SWOT analysisNSE:EPL EPL Ltd. - A 360° Analysis: Technical, Fundamental, and SWOT Overview⤵️ ✅ Current Price Action & Historical Breakouts: Multi-Decadal Breakout: ↳ In the early 2000s, EPL Ltd. broke out from a long consolidation, signaling a shift in market sentiment. Major Rally: ↳ Post-2012, the stock rallied by 573.18% over 1,400 days following a breakout. ↳ Another breakout in 2020 led to a 138.83% gain over 305 days. Current Situation: ↳ The stock is consolidating in a wedge pattern near ₹216.39. ↳ Resistance around ₹250-₹260; support at ₹197.04 (50-month EMA) and ₹183.15 (200-month EMA). ✅ Volume Trends: ↳ Strong institutional participation during past breakouts. ↳ Recent lower volumes indicate a cautious approach by large investors. ✅ Key Levels to Watch: Resistance: ↳ ₹250-₹260. Support: ↳ ₹197.04 (50-month EMA), ₹183.15 (200-month EMA), ₹86.00, ₹72.53, ₹52.81. ✅ Technical Outlook: ↳ A breakout above the wedge could signal a new uptrend. ↳ A breakdown may lead to retesting lower support levels. 🔰Fundamental Analysis ✅ Quarterly & Full-Year Performance: Quarterly Highlights: Revenue Growth: ↳ 6.2% YoY increase. EBITDA Growth: ↳ 16.5% YoY increase. Adjusted PAT: ↳ 22% growth. EBITDA Margin: ↳ Improved to 18.5%, up by 164 basis points. Reported PAT: ↳ Declined by 73.5% due to exceptional items. Full-Year Highlights: Revenue Growth: ↳ 6% YoY increase. EBITDA Growth: ↳ 19.2% YoY. EBITDA Margin: ↳ Expanded by 202 basis points. Adjusted PAT Growth: ↳ 28% YoY. ROC: ↳ Improved to 14.7%, up 148 basis points YoY. ✅ Strategic Shifts & Future Initiatives: Category Mix: ↳ Personal Care and Beyond segments now contribute 47% to total revenue. Sustainability: ↳ Sustainable sales doubled to 21%. ↳ Received multiple awards for innovation, employer excellence, and CSR. Brazil Greenfield Project: ↳ Progressing well, expected to meet significant demand. Regional Performance: Americas: ↳ Margin expansion to 9%, with efforts to improve US operations. Europe: ↳ Restructuring aimed at achieving mid-teens margins. Pharma & B&C Segments: ↳ Focus on Beauty & Cosmetics with Neoseam technology. ↳ Longer conversion times in the Pharma segment due to regulatory hurdles. ✅ Financial Management: Interest Costs: ↳ Increased due to Brazil operations, expected to remain steady. Debt Reduction: ↳ Evaluated based on cash flow and dividends. ✅ Dividend: ↳ Proposed increased final dividend of Rs.2.30 per share. 🔰SWOT Analysis ✅Strengths: Market Leadership: ↳ Global leader in laminated plastic tubes. Diverse Client Base: ↳ Serves various industries, ensuring stable revenue. Strong Financials: ↳ Healthy balance sheet, low debt, strong cash flow. ✅Weaknesses: Raw Material Dependency: ↳ Sensitive to fluctuations in raw material prices. Geographical Concentration: ↳ Significant revenue from a few key markets. ✅Opportunities: Sustainability Trends: ↳ Growing demand for eco-friendly packaging. Emerging Markets: ↳ Growth opportunities with expanding middle class. Mergers & Acquisitions: ↳ Potential to strengthen market position. ✅Threats: Regulatory Risks: ↳ Increasing regulations around plastic usage. Intense Competition: ↳ Faces competition from global and local players. Economic Slowdowns: ↳ Impact on demand in FMCG sector during downturns. 🔰Conclusion EPL Ltd. presents a compelling investment case with its strong technical setup, robust financial performance, and strategic initiatives aimed at sustainable growth. The company’s focus on expanding its presence in high-margin segments like beauty and cosmetics, coupled with its commitment to sustainability, positions it well for future success. However, investors should be mindful of the risks associated with raw material volatility and regulatory changes. With a strong operational track record and ongoing efforts to optimize its global footprint, EPL Ltd. remains a key player to watch in the packaging industry. The stock's technical setup suggests it is at a crucial point, with potential for both upside breakout and downside risk. A disciplined approach, considering both technical signals and fundamental strengths, will be key for investors navigating this opportunity. Disc: SEBI Certified RA, no recommendation to buy or sell. Invested (PWI LAB portfolio). Share your thoughts in the comments below. Give the post a boost if you found it helpful. Share with friends and family who will benefit from this analysis. Follow us for more insightful analysis and updates!
NSE:EPLLong
by Peaceful-Weekend-Investing
ITDCEM Going 2 Break All Time High With Huge Positive NumbersNSE:ITDCEM Over 90 years of rich industry experience ...................................................................................... ...................................................................................... Company is expected to give good quarter, Company has delivered good profit growth of 26.4% CAGR over last 5 years ...................................................................................... ...................................................................................... Amongst the leading infrastructure & construction company in Thailand for over 60 years. ...................................................................................... ...................................................................................... Received ‘The Royal Seal of Garuda’ in 1985 - Highest and most honorable achievement for civilian companies in Thailand Global presence in India, Bangladesh, Lao PDR, the Philippines, Vietnam, Africa etc. Access to the latest technology and know-how, international design and engineering as well as skilled personnel to augment our local strength. ...................................................................................... ...................................................................................... MULTI YEAR REVENUE VISIBILITY ORDERBOOK OF RS 18,536 CRORE. • Secured orders worth over Rs 1,053 crore in Q1 FY25. • Clientele comprises of Government (48%), PSU (17%) and Private Sector (35%). • Established presence in India with 13 states / 1 union territory and is currently executing project in Sri Lanka and Bangladesh ...................................................................................... ...................................................................................... Major Projects under execution worth of Rs 6,401 crore. Marine project in Bangladesh. West Container Terminal in the Port of Colombo, Sri Lanka. Balance Outer Harbour Works in Andhra Pradesh. Piers, Landside Tunnels & Building in Karwar, Karnataka. Udangudi project in Tamil Nadu. Wharf and Approach trestle works at JNPT in Maharashtra. Captive Oil Jetty at Kamarajar Port in Tamil Nadu. Third Berth (Jetty) at Dahej LNG Terminal in Gujarat ...................................................................................... ...................................................................................... Major Projects under execution worth of Rs 3,936 crore. Underground tunneling and stations for metros in Chennai, Bengaluru, Mumbai and Kolkata. Elevated metro stations and buildings in Kolkata Depot metro building in Surat Modification & Refurbishment of terminal buildings in Ahmedabad airport ...................................................................................... ...................................................................................... Major Projects under execution worth of Rs 2,717 crore Six laning road project in Uttar Pradesh ...................................................................................... ...................................................................................... Major Projects under execution worth of Rs 2,341 crore Redevelopment of Residential colony at Kasturba Nagar in New Delhi. Circuit bench of Calcutta High Court at Jalpaiguri in West Bengal. Thal Sena Bhawan in Delhi. Aerospace museum at AF station in Palam, Delhi. Piling and Civil work for Coke Oven Project at Hazira plant in Gujarat. Construction of buildings for Sikkim University ...................................................................................... ...................................................................................... Major Projects under execution worth of Rs 2,120 crore Railway tunnels in West Bengal and Sikkim. Civil & Hydro-Mechanical Works of 500 MW Hydel Power, Pumped Storage Project in Andhra Pradesh. Water conveyor system of lined gravity canal/tunnels in Telangana
NSE:ITDCEMLong
by iism-ExpertTrading
3
CERA SANITARYWARE is At ALL TIME HIGH with Positive NumbersNSE:CERA Established market position in the sanitaryware segment and diversified revenue profile: Cera has a track record of nearly three decades, strong brand image and a large retail network in the sanitaryware industry. It is one of the leading players in this segment, which has been one of the largest revenue contributors over the years, accounting for around 47% of turnover in fiscal 2024. Over the past few years, Cera has been leveraging its strong market position in the domestic sanitaryware industry by venturing into related business segments, such as faucets, tiles and wellness and allied products, thus becoming a complete bathroom solutions provider. Successful diversification into related businesses has helped lower dependence on the sanitaryware business, besides improving the efficiency of the distribution network. Intense competition and volatile demand from the real estate sector led to sluggish revenue growth in fiscal 2024. However, with improving demand prospects expected and demand from real estate to remain healthy with projects reaching completion over the next 2-3 years, revenue in the sanitaryware segment is likely to see healthy growth over the medium term. Sanitaryware, faucetware, tiles and other products accounted for 47%, 36%, 10% and 7%, respectively, of the company’s turnover in fiscal 2024. Also, the company has presence across various domestic markets in south, east, north and west, providing adequate geographical diversity. Healthy financial risk profile: Networth was healthy at Rs 1,358 crore and gearing low at 0.02 time as on March 31, 2024. Debt protection metrics are expected to remain strong, in the absence of large, debt-funded capex and healthy operating performance. Cash accrual is expected at ~Rs 180-230 crore per annum and will comfortably fund the capex plans in fiscals 2025 and 2026 and incremental working capital requirement. Hence, reliance on debt is expected to be low, sustaining strong debt metrics over the medium term. Company is almost debt free. Company has been maintaining a healthy dividend payout of 31.4%. ZERO DEBT COMPANY Cash and Cash Equivalents of Rs. 828 crore; primarily liquid investments. • No Contingent Liabilities for Joint Ventures POSITIVE FREE CASH FLOW EVERY YEAR Consistent cash generation each year • Annual Capex requirement < Free Cash flow generation. • Increasing gap between annual cash flow generation less dividend outflow and capex. • Regularly paid dividends for the last 30 years + AGGRESSIVE FOCUS ON CAPEX Fixed Asset turnover of ~5.6x. • Uniform organization-wide policy to monitor receivables – credit not used to drive revenues. • ERP automatically shuts down fresh supplies to dealers / customers with dues in excess of 45-60 days Multilayered Marketing Infrastructure. ⚫ Enhances retail experiences, retailer owned ⚫ Currently 1,067 Cera Style Centre’s (CSC’s) operational ⚫ Over 1,400 CSCs planned in the next 3-4 years ⚫ Minimum size of showroom ranges between 100 sq. ft. - 500 sq. ft. Multilayered Marketing Infrastructure ⚫ 11 CERA Style Studios (CSS): Ahmedabad / Mumbai / Bengaluru / Kolkata / Cochin / Hyderabad / Trivendrum / Morbi / Kadi / Mohali & Lucknow (Upcoming) ⚫ Discerning customers including influencer's can touch and feel products ⚫ No sales orientation / pressure ⚫ The average size these company owned showroom are approx. 7,000 sq.ft. ⚫ With more than 14,000 sq.ft. of display, Hyderabad CSS is the largest company showroom in this industry
NSE:CERALong
by iism-ExpertTrading
... Pure Technical Tukka ... KHADIM INDIA LTD ... NSE:KHADIM as per Studies Thought by Institutions ... we are assuming -6.6 % of SL and Going for the Target of +24.15% ... That means ... we are Maintaining around 1:4 RR (Risk Reward Ratio) This Trade is Pure Tukka ... Fundamental Ratio's Are Not Satisfying ... Every Analyst Would Say that Stay Away From Khadim India Ltd ... Then Why Our Page is Sharing This Stock As Buying Suggestion ? Entering a Trade with a STOP LOSS ... SL of -6.6% .... is not a Bad Practice .... if anyone is Afraid of SL then He/She should stop or quit Trading ...
NSE:KHADIMLong
by iism-ExpertTrading
ELECTCAST 3rd Time Knocking its All Time High with Weekly HammerNSE:ELECTCAST The company was incorporated in November 1955, as Dalmia Iron & Steel Ltd and re-incorporated under the name of ECL in May 1965. ECL manufactures DI pipes with combined installed capacity of 7,45,000 MTPA. Combined production capacity for DI fittings and cast iron pipes is 21,000 MTPA and 90,000 MTPA, respectively. Through backward integration, the company also operates a blast furnace, coke oven and waste heat recovery-based power plant. Plants are in Khardah and Haldia in West Bengal, Elavur in Tamil Nadu, and Srikalahasthi in Andhra Pradesh. Strengths: Established position in the pipes industry with significant backward integration: The three-decade-long experience of the promoters in the ductile iron (DI) pipes industry has helped them establish significant market presence, expand production capacities, and undertake backward integration over the years. The facility is already utilised by over 90% and ECL plans to further add capacity of more than 2.5 lakh metric tonne per annum (MTPA) over the next two fiscals. This will enable the company to retain its leadership position in the DI pipe market. The company maintains strong trade relationships with reputed overseas customers and all major players in the domestic market. Limited competition, owing to large capital requirement and necessity to have critical accreditations and customer approvals, bolster the business risk profile. Performance is further supported by improving global and domestic demand, as reflected in a strong order book providing healthy revenue visibility. Healthy financial risk profile: Networth and gearing have improved to Rs 5,111 crore and 0.44 time, respectively, as on March 31, 2024 (Rs 4,376 crore and 0.6 time, respectively, a year earlier), backed by better profitability and hence, steady accretion to reserves. Lower dependence on external debt and better working capital management should also aid the financial risk profile. Debt protection metrics remain comfortable with interest coverage and net cash accrual to adjusted debt ratios at 5.7 times and 0.34 time, respectively, in fiscal 2024. Order Book 6 lakh tonnes let say, so about nine to 10 months of Healthy Order Book. worth of Around Rs. 4,500 crores approximately. Financial Highlights Revenues at INR 7,580 Crores, Highest ever yearly EBITDA and PAT at INR 1,281 Crores and INR 740 Crores, respectively in FY24 ➢ EBITDA margin and PAT margin at 16.9% and 9.8%, respectively in FY24 ➢ Adjusted FY24 ROCE at 19.0% (FY23 - 13.0%) and ROE at 19.3% (FY23 - 11.2%) ➢ Strong Order Book visibility of 10 months Other Financial Metrics EBITDA grew by 50.9% YoY to INR 346 Crores in Q4FY24, the EBITDA margin expanded by 495 bps YoY to 17.0%. • Highest ever PAT of INR 227 Crores, up by 153.8% YoY in Q4FY24, PAT margin expanded by 645 bps YoY to 11.1%. • Decline in interest cost by 33.3% during the quarter. Effective Positive Policies Jal Jeevan Mission (JJM): Driving Water Infra Demand ➢ The Government’s flagship scheme - Outlay of INR 3.60 lakh crores ➢ Providing water supply by to every crore rural household at a capacity of at least 55 litres per capita, per day (lpcd) by 2024 ➢ Providing Functional Household Tap Connections (FHTCs) to 19.4 crore rural households and village institutions ➢ Prioritising quality-affected villages (drought prone & desert areas Additional Government Schemes Driving Water Infra Spending AMRUT 2.0: INR 2,99,000 Crores (Launched by Hon’ble PM on 1st Oct 2021) ➢ Aims to provide 2.68 Crore water taps connections in 4,800 statutory towns ➢ New 2.64 Crore Sewerage/Septage services in 500 AMRUT cities
NSE:ELECTCASTLong
by iism-ExpertTrading
IRCTC - Ready for a HUGE move? Aiming around 80%+ gains! IRCTC is set to double once it clears key resistance levels! --- Weekly TF View: Here's the plan: - Critical Level: Watch for a daily candle close above ₹1000. This signals the first entry point around ₹1027. - All-Time High Alert: If the weekly candle closes above ₹1300, prepare for a potential Marubozu candle, indicating strong bullish momentum. This will be our second entry point. - Strategy: Entering before the breakout to catch the bottom. Remember, risk management is crucial. The market is supreme; we adapt. - Price is bouncing from the important fibonacci support area. Showcasts buyers are strong! Let’s wait and watch the show unfold! --- Stay tuned for updates as IRCTC approaches these critical levels. Happy trading! Disclaimer: This is NOT a buy/sell recomendation. This post is meant for learning purposes only. Please, do you due diligence before investing. Thanks & Regards, Anubrata Ray
NSE:IRCTCLong
by SuperNova396
9
B.L Kashyap & Sons Increasing Strength Can Be Held For Long-TermB.L.Kashyap & Sons Ltd is an EPC company engaged in the business of Construction of Buildings High-Rise Residential and Commercial Complexes, IT Parks, Institutional Buildings. Total: 1,733.68 Cr Order value Company has delivered good profit growth of 71.0% CAGR over last 5 years Projects • More than three decades of rich expertise. • Completed 250 + projects and more than 140 million sq. ft. Design Build Projects • National High-Speed Railways • Sabarmati Station • DLF Downtown • Embassy Flipkart • Redevelopment of Gomti Nagar Station • Hero Honda Motor Plant • Jaipur & Chennai Metro Company coming out of CDR – Moving towards Zero Debt • In the light of global meltdown during 2010 -13 operations of BLK were impacted resulting in stress on the company • BLK entered CDR in 2014 • Currently the company has no long-term debt and has pared its consolidated debt. • Reduction of Debt from 700 to ~ 270 • Currently the company only has CC and BG limits De-risking business model – Residential to Commercial & Governmen • Company has been awarded total orders during financial year 2022-23 to the tune of Rs. 818.9 Cr • The order book closed at Rs. 2402 crore for the year ended March 31, 2023 • Orders worth approx. INR 658 crore and INR 247 crore awarded during the first and second quarter of FY2023 - 24 • Ending 30th June 2023 and the order book stood at approx. Rs. 2838 cr. • Total Order Book stands at Rs. 3005 Cr as of September 2023 • During the quarter, orders were received across multiple segments like railways, business parks, educational institutions, and residential complex Growth driven to Profitability focus • The company has planned capex of approximately INR 25 crores during FY24. Capex for FY22 and FY23 was Rs. 8 Cr and Rs. 19 Cr respectively • BLK is looking at increasing its footprint in the infrastructure space related to its core business, which is high quality structures and their associated works.
NSE:BLKASHYAPLong
by iism-ExpertTrading
ASHOKA METCAST LTD Chota Packet Bada DhamakaStock is trading at 0.58 times its book value Promoter Holding Increased 9.66 % over Last 6 Years From Year 2020 to 2024 Company Have Gradually Purchased their Fixed Assets of 20.57 CR . in Year March 2018 Company Reported Total Annual Sales of 19.17 CR Now in Year March 2024 Company Reported Annual Sales of 66.25 CR Net Cash Flow Is Healthy Cash Convertion Cycle and Working Capital Days have Also Decreased Reserves and Equity Capital showing Increasing Strength
NSE:ASHOKAMETLong
by iism-ExpertTrading